

ISSUE DATE October 21, 2021	EFFECTIVE DATE August 23, 2021	NUMBER 08-21-07
SUBJECT Naloxone Distribution by Federally Qualified Health Centers and Rural Health Clinics		BY  Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

PURPOSE:

The purpose of this bulletin is to inform Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC) of the procedure for submitting claims to the Department of Human Services (Department) for a take-home supply of naloxone distributed to Medical Assistance (MA) beneficiaries.

SCOPE:

This bulletin applies to all FQHCs and RHCs enrolled in the MA Program that render services to MA beneficiaries in the fee-for-service and managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND/DISCUSSION:

To support the provision of services in an opioid treatment program, MA enrolled FQHCs and RHCs are to bill for the provision of a take-home supply of nasal or injectable naloxone to MA beneficiaries. However, as these services are to be provided as part of a FQHC/RHC billable encounter and are included as part of the FQHC's or RHC's Prospective Payment System (PPS) rate under procedure code T1015, the Department did not previously have a method in place to track the provision of an opioid treatment supply in the FQHC and RHC settings.

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

Fee-for-service provider service center: 1-800-537-8862

Visit the Office of Medical Assistance Programs website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>.

On August 23, 2021, the Department issued [MA Bulletin 99-21-04](#), titled “2021 Healthcare Common Procedure Coding System (HCPCS) Updates, Fee Adjustments and Other Procedure Code Changes.” MA Bulletin 99-21-04 includes the addition of two procedure codes to identify the distribution of a take-home supply of nasal or injectable naloxone. These codes were added to enable the Department to identify the provision of a take-home opioid treatment supply to MA beneficiaries.

PROCEDURE:

The Department updated the [MA Program Fee Schedule](#) to include the procedure codes for the submission of claims that include the provision of a take-home supply of naloxone for MA beneficiaries. FQHCs and RHCs are to bill procedure code T1015 to receive payment based on their provider-specific PPS payment rate, when providing an encounter that includes providing beneficiaries with a take-home supply of naloxone. In addition, they are to include the appropriate zero-pay HCPCS code from the chart below on a separate claim line so the Department can track the distribution.

<u>Code</u>	<u>Code Description</u>
G2215	Take home supply of nasal naloxone (provision of the services by a Medicare enrolled opioid treatment program); list separately in addition to code for primary procedure
G2216	Take home supply of injectable naloxone (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure

FQHCs and RHCs are to refer to the instructions for submitting claims for encounters that include naloxone distribution in this MA Bulletin, as well as the instructions in the [MA Program’s Provider Handbook and Billing Guides](#).